Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board

Company Overview - Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on treating immune dysregulation [4] - The company's lead asset is AVTX-009, an anti-IL-1β monoclonal antibody targeting inflammatory diseases [4][5] Leadership Changes - Michael Heffernan has been appointed as the new Chairman of the Board, succeeding Dr. Garry Neil, who remains as a Board member and CEO [1][2] - Dr. Neil emphasized the importance of Heffernan's experience in building biopharmaceutical companies and driving shareholder value during a critical growth phase for Avalo [2] Strategic Direction - Heffernan expressed confidence in Avalo's potential for success, citing a strong management team, promising mechanisms of action, and sufficient capital to achieve transformative data from the ongoing Phase 2 LOTUS trial for hidradenitis suppurativa [2] - The company is considering indication expansion as part of its strategic growth [2] Product Information - AVTX-009 is designed to bind to interleukin-1β (IL-1β) with high affinity, neutralizing its activity, which is crucial in the inflammatory process [5] - The inhibition of IL-1β is believed to be effective in treating hidradenitis suppurativa and various inflammatory diseases across dermatology, gastroenterology, and rheumatology [5]